PATENT CLAIM ANALYSIS

Application Number: 15779435
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "235800"]

Abstract:
The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R 1  represents a hydrogen atom, an optionally substituted alkyl group, or the like; R 2  represents a hydrogen atom, a halogen atom, or the like; and R 3  represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Claim (Index 3):
The compound according to  claim 2 , wherein\n the substituent of the (1) optionally substituted alkyl group represented by R 1  is 1 to 3 groups independently selected from the group consisting of a halogen atom; a hydroxy group; a cyano group; an alkoxy group optionally substituted with an aryl group; an alkanoyl group; an aryl group optionally substituted with a group selected from the group consisting of an alkylsulfonyl group and an aminosulfonyl group; an optionally partially hydrogenated heteroaryl group optionally substituted with 1 to 2 groups independently selected from the group consisting of an oxo group and a hydroxy group; an aliphatic heterocyclic group optionally substituted with 1 to 2 oxo groups; an amino group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group, a heteroaryl group, an alkoxycarbonyl group, an alkylsulfonyl group, and an aminosulfonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; and a sulfonyl group optionally substituted with a group selected from the group consisting of an aliphatic heterocyclic group optionally substituted with a hydroxy group and an amino group optionally substituted with 1 to 2 alkyl groups; the substituent of the (2) optionally substituted cycloalkyl group, (3) optionally substituted aryl group, (4) optionally substituted heteroaryl group, (5) optionally substituted aliphatic heterocyclic group, and (6) optionally substituted alkanoyl group represented by R 1  is 1 to 3 groups each independently selected from the group consisting of a halogen atom; a hydroxy group; a cyano group; an alkyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a halogen atom, a hydroxy group, and a cyano group; an alkoxy group optionally substituted with an aryl group; an alkanoyl group; an aryl group optionally substituted with a group selected from the group consisting of an alkylsulfonyl group and an aminosulfonyl group; an optionally partially hydrogenated heteroaryl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a hydroxy group and an oxo group; an aliphatic heterocyclic group optionally substituted with 1 to 2 oxo groups; an amino group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group, a heteroaryl group, an alkoxycarbonyl group, an alkylsulfonyl group, and an aminosulfonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; and a sulfonyl group optionally substituted with a group selected from the group consisting of an aliphatic heterocyclic group optionally substituted with a hydroxy group and an amino group optionally substituted with 1 to 2 alkyl groups; wherein said aryl moiety in the optionally substituted aryl group represented by R 1  is a 6 to 10 membered monocyclic or bicyclic aryl; said heteroaryl moiety in the optionally substituted heteroaryl group represented by R 1  is a 5 to 10 membered monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group represented by R 1  is a 4 to 8 membered monocyclic aliphatic heterocyclic group comprising 1 to 2 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; said aryl moiety in the optionally substituted aryl group in the substituent of the group represented by R 1  is a 6 to 10 membered monocyclic or bicyclic aryl; said heteroaryl moiety in the optionally partially hydrogenated and optionally substituted heteroaryl group in the substituent of the group represented by R 1  is a 5 to 10 membered monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group in the substituent of the group represented by R 1  is a 4 to 8 membered monocyclic aliphatic heterocyclic group comprising 1 to 2 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; R 2  represents a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group, or an alkoxy group; Ring B represents an aryl group, a cycloalkyl group, or a heteroaryl group; R 4 , R 5 , and R 6  represent each a group independently selected from the group consisting of a hydrogen atom; a halogen atom; an optionally substituted alkyl group; an optionally substituted cycloalkyl group; an optionally substituted heteroaryl group; an optionally substituted aliphatic heterocyclic group; and an amino group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group optionally substituted with a carboxyl group; wherein the substituent of the (1) optionally substituted alkyl group represented by R 4 , R 5 , or R 6  is 1 to 2 groups independently selected from the group consisting of a hydroxy group; a halogen atom; an oxo group; a cyano group; a heteroaryl group optionally substituted with a group selected from the group consisting of a hydroxy group and an oxo group; a carboxyl group; an alkoxycarbonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; an alkylsulfonyl group; an alkylsulfonylamino group; an alkylsulfonylaminocarbonyl group; and an aminosulfonylaminocarbonyl group optionally substituted with 1 to 2 alkyl groups; the substituent of the (2) optionally substituted cycloalkyl group, (3) optionally substituted heteroaryl group, and (4) optionally substituted aliphatic heterocyclic group represented by R 4 , R 5 , or R 6  is 1 to 2 groups each independently selected from the group consisting of a hydroxy group; a halogen atom; an oxo group; a cyano group; an alkyl group; a heteroaryl group optionally substituted with a group selected from the group consisting of a hydroxy group and an oxo group; a carboxyl group; an alkoxycarbonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; an alkylsulfonyl group; an alkylsulfonylamino group; an alkylsulfonylaminocarbonyl group; and an aminosulfonylaminocarbonyl group optionally substituted with 1 to 2 alkyl groups; wherein said heteroaryl moiety in the optionally substituted heteroaryl group represented by R 4 , R 5 , or R 6  is a 5 to 10 membered monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group represented by R 4 , R 5 , or R 6  is a 4 to 8 membered monocyclic aliphatic heterocyclic group comprising 1 to 2 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; and said heteroaryl moiety in the optionally substituted heteroaryl group in the substituent of the group represented by R 4 , R 5 , or R 6  is a 5 to 10 membered monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 93.0
- Lexical Diversity: 2.03846
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15313407', '15305587', '13154144', '12919973', '14891845']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7200231398305605
- 35 USC 102 Novelty (BERT): 0.5652276440871533
- Combined Prediction Score: 0.7045435902562198
- Mean Citation Score: 313.940092
- Max Citation Score: 427.80472
- Similarity Product: 389.2978950669575

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test